ARS Pharmaceuticals, Inc. SPRY EBITDA

EBITDA at other companies

Aquestive Therapeutics, Inc.AQST

-$8.09M+28.0%

ViatrisVTRS

$678.6M-25.5%

AMP

Amphastar PharmaceuticalsAMPH

$54.04M-4.9%

Neuropace, Inc.NPCE

-$5.04M+37.7%

Eton Pharmaceuticals, Inc.ETON

$3.55M+553%

Talphera, Inc.TLPH

-$3M—

FAQ

What is ARS Pharmaceuticals, Inc.'s EBITDA?

ARS Pharmaceuticals, Inc. (SPRY) reported EBITDA of -$59.75M in Q1 2026.

How has ARS Pharmaceuticals, Inc.'s EBITDA changed year-over-year?

ARS Pharmaceuticals, Inc.'s EBITDA decreased by 61.9% year-over-year, from -$36.9M to -$59.75M.

What is the long-term trend for ARS Pharmaceuticals, Inc.'s EBITDA?

Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s EBITDA has grown at a 71.9% compound annual growth rate (CAGR), from -$35.07M to -$178.08M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.